Orakl Oncology funding, valuation and investors

Product & use cases

For a pharmaceutical buyer, Orakl's O-Predict uses tumour organoid drug-response assays, biological measurements and longitudinal patient clinical data to forecast treatment-arm results and examine biomarkers or drug combinations; O-Target investigates new therapeutic targets. This is research decision support, not an approved therapy or clinical diagnosis. Contracts and per-program pricing have not been disclosed. The SCOPE study was a non-peer-reviewed preprint comparing predictions to published clinical trial arms, not independent prospective validation of 90% accuracy in individual patients.

• Illustrative buyer workflow: specify tumour indication and trial decision; obtain properly consented patient-derived biological data; perform organoid drug screening; combine with molecular and clinical information; model response and progression-free survival; check uncertainty and independently validate predictions before trial changes.
• Research colorectal and pancreatic cancer responses: SCOPE's retrospective preprint compared forecasts with 32 treatment arms from 23 previously reported trials.
• Generate and test candidate biomarkers, drug combinations or oncology targets for further laboratory validation and clinical development.

Key facts

• November 12, 2026: $34M Series A co-led by Norrsken VC and Singular; $50M company-reported funding since inception.
• Founded in 2023 by Fanny Jaulin, Diane-Laure Pagès and Gustave Ronteix.
• Norrsken says 18 of the world's 20 largest pharmaceutical companies appear in the commercial pipeline; this is not a verified paid-customer count.
• April 2026 SCOPE medRxiv preprint: retrospective trial-arm model assessment, 32 arms from 23 published trials; not peer-reviewed.

Competitive landscape

Edge: Hospital-linked tumour specimens and longitudinal clinical/drug-response data could differentiate from purely computational models, but exclusivity, robustness and economic moat are not independently proven.

The key buyer diligence is blinded prospective clinical validation, representativeness of patient samples, costs/timing per assay, data rights, compliance and whether predictions improve downstream trial success. An Orakl-authored SCOPE preprint reports mPFS prediction R²=0.85 across published trial arms and the better arm identified in 7/8 comparisons, not 90% independently verified prospective patient-level accuracy.

• Owkin adjacent

  Multimodal oncology AI and biomarker research, not identical to living organoid screening.

• insitro adjacent

  Experimental biology plus machine learning in pharmaceutical research; different datasets and operating model.

• Patient-derived organoid CRO laboratories alternative

  Experimental functional screening without Orakl's integrated AI trial-forecasting package.

Market / IPO context